Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Monday, September 5, 2016

MS Relapses During Natalizumab Therapy Traced to Drug’s Greater Impact on Regulatory T-cells


                                                                  
  

Click here to receive MS news via e-mail



Natalizumab (Tysabri) harnesses multiple sclerosis (MS) activity by targeting CD49, a molecule on the surface of immune cells. Now, researchers found that the drug reduces the factor on regulatory T-cells to a greater extent than on inflammatory T-cells — a mechanism that might explain disease exacerbation during treatment.
The molecule under investigation in the study, CD49, is the main factor governing migration of immune cells to the central nervous system. By blocking its actions, natalizumab is highly effective in inducing MS remission. Some patients, however, experience relapses and disease progression while under treatment.
Natalizumab treatment does not necessarily block all CD49; earlier studies have shown that the antibody is able to bind between 60 percent and 100 percent of all available molecules. Scientists also do not understand how effective natalizumab treatment is in reducing CD49 on different types of immune T-cells.






MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: